Among those taking beta blockers, women had a 4.6 percent higher rate of heart failure than men after being admitted to the hospital with acute coronary syndrome, according to the researchers.

Heart Failure Rx: Pacemakers, Not Beta Blockers, May Be Best For Some Patients Date: November 7, 2006 Source: Johns Hopkins Medical Institutions Summary: Researchers at Johns Hopkins have reported ...

The study ran from 2018 to 2023. "Beta blocker treatment led to a modest increase in depressive symptoms" for heart attack survivors who weren't in heart failure, the researchers reported.

Their newer study finds the drugs might even pose harm. They looked at data from more than 800 heart attack survivors without heart failure who had either been prescribed a beta-blocker or some ...

Beta-blockers benefit women as much as men, according to one of the largest studies to examine gender differences in treating heart failure, researchers report in today’s rapid access issue of ...

There was a significant reduction in all-cause mortality in patients with sinus rhythm on β-blockers (hazard ratio, 0.73; 95% confidence interval, 0.67–0.80; P <0.001), but not in patients with ...

Heart failure itself poses a considerable societal burden. [2, 3] In the US, the approximate prevalence of heart failure is 4.79 million, with an incidence of 550 000 new cases a year and ...

Traditional beta-blockers target beta1-adrenergic receptors, which helps to prevent heart cells from dying and exacerbating a case of heart failure. However, beta1-adrenergic are also responsible for ...

DALLAS, March 12 – Beta-blockers benefit women as much as men, according to one of the largest studies to examine gender differences in treating heart failure, researchers report in today’s ...

Among mild to moderately symptomatic heart-failure patients with impaired LVEF, initiation of treatment with bisoprolol followed by enalapril, as compared with the opposite sequence of drugs ...

Beta-blocker drugs appear to help people with heart failure, a finding that may ease concerns about possible adverse side effects in patients with the deteriorating condition, a study says.

(HealthDay)—Patients with heart failure and atrial fibrillation given β-blockers have no significant reduction in all-cause mortality compared to those given placebo treatment, according to ...